Due to the presentation and immunogenicity of GPC3 on the cell surface, GPC3 has attracted people’s attention as an attractive therapeutic target for immunotherapy for HCC patients [10,12]. The gene discussed is GPC3; the disease is hepatocellular carcinoma.